Gene:
ABL1
ABL proto-oncogene 1, non-receptor tyrosine kinase

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for bosutinib and ABL1,BCR
  2. FDA Label for busulfan and ABL1,BCR
  3. FDA Label for dasatinib and ABL1,BCR
  4. FDA Label for homoharringtonine and ABL1,BCR
  5. FDA Label for imatinib and ABL1,BCR,KIT
  6. FDA Label for nilotinib and ABL1,BCR
  7. FDA Label for ponatinib and ABL1,BCR
  8. EMA Label for bosutinib and ABL1,BCR
  9. EMA Label for dasatinib and ABL1,BCR
  10. EMA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRB
  11. EMA Label for nilotinib and ABL1,BCR
  12. EMA Label for ponatinib and ABL1,BCR
  13. PMDA Label for dasatinib and ABL1,BCR
  14. PMDA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRA
  15. HCSC Label for bosutinib and ABL1,BCR

last updated 12/16/2013

1. FDA Label for bosutinib and ABL1,BCR

Genetic testing required

Summary

The FDA-approved drug label for bosutinib (BOSULIF) notes that it is intended for adults with chronic, accelerated or blast phase Philadelphia chromosome-positive chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.

There's more of this label. Read more.


last updated 10/25/2013

2. FDA Label for busulfan and ABL1,BCR

Actionable PGx

Summary

The busulfan FDA-approved drug label states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome. Testing for the BCR-ABL1 gene fusion is not mentioned in the drug label.

There's more of this label. Read more.


last updated 10/25/2013

3. FDA Label for dasatinib and ABL1,BCR

Genetic testing required

Summary

The FDA-approved drug label for dasatinib (SPRYCEL) notes that it is intended for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL) and resistance or intolerance to prior therapy.

There's more of this label. Read more.


last updated 12/18/2013

4. FDA Label for homoharringtonine and ABL1,BCR

Informative PGx

Summary

The FDA-approved drug label for omacetaxine mepesuccinate (homoharringtonine; SYNRIBO) notes that it is intended for adults with chronic or accelerated phase chronic myeloid leukemia (CML). The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).

There's more of this label. Read more.


last updated 10/25/2013

5. FDA Label for imatinib and ABL1,BCR,KIT

Genetic testing required

Summary

The decision of whether to treat patients with imatinib is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.

There's more of this label. Read more.


last updated 03/18/2016

6. FDA Label for nilotinib and ABL1,BCR

Genetic testing required

Summary

Nilotinib is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 (rs8175347) are at an increased risk of hyperbilirubinemia when taking nilotinib (testing is not required for UGT1A1).

There's more of this label. Read more.


last updated 12/19/2013

7. FDA Label for ponatinib and ABL1,BCR

Actionable PGx

Summary

The FDA-approved drug label for ponatinib (Iclusig) states that it is intended for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including those with the BCR-ABL T315I mutation. The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).

There's more of this label. Read more.


last updated 03/31/2014

8. EMA Label for bosutinib and ABL1,BCR

Genetic testing required

Summary

The EMA EPAR for bosutinib (Bosulif) contains information regarding the indication of the drug in adult patients with Philadelphia chromosome positive chronic myelogenous leukaemia. This is due to its mechanism of action - the drug inhibits the abnormal BCR-ABL kinase that promotes chronic myelogenous leukaemia.

There's more of this label. Read more.


last updated 10/25/2013

9. EMA Label for dasatinib and ABL1,BCR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) highlights information regarding the indication of Dasatinib (Sprycel) in patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia or acute lymphoblastic leukaemia.

There's more of this label. Read more.


last updated 10/25/2013

10. EMA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRB

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.

There's more of this label. Read more.


last updated 10/27/2013

11. EMA Label for nilotinib and ABL1,BCR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for nilotinib (Tasigna) states it is indicated for patients who have Philadelphia chromosome-positive (presence of a BCR-ABL1 gene fusion) chronic myelogenous leukemia (CML). The label differs from that of the FDA as it does not contain any information regarding UGT1A1 genotype.

There's more of this label. Read more.


last updated 06/13/2014

12. EMA Label for ponatinib and ABL1,BCR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for ponatinib (Iclusig) states that indications of the drug include patients with Philadelphia chromosome positive (BCR-ABL1 gene fusion) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or patients who have the BCR-ABL T315I mutation, due to its mechanism of action as an inhibitor of BCR-ABL and inhibitor of mutant forms of the ABL kinase.

There's more of this label. Read more.


last updated 01/26/2015

13. PMDA Label for dasatinib and ABL1,BCR

Genetic testing required

Summary

The PMDA package insert for dasatinib states that it is indicated for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

There's more of this label. Read more.


last updated 01/26/2015

14. PMDA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRA

Genetic testing required

Summary

The PMDA package insert for imatinib contains pharmacogenetic information regarding the indication of the drug in patients with the Kit (CD117)-positive tumors, hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFR a rearrangement, or Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.

There's more of this label. Read more.


last updated 06/08/2015

15. HCSC Label for bosutinib and ABL1,BCR

Genetic testing required

Summary

The product monograph for bosutinib (BOSULIF) states that it is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for ABL1

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
rs121913459 NC_000009.11:g.133748283C>T, NC_000009.12:g.130872896C>T, NG_012034.1:g.164016C>T, NM_005157.5:c.944C>T, NM_007313.2:c.1001C>T, NP_005148.2:p.Thr315Ile, NP_009297.2:p.Thr334Ile, XM_005272177.1:c.998C>T, XP_005272234.1:p.Thr333Ile
C > T
SNP
T315I
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  ABL
Alternate Symbols:  JTK7; c-ABL; p150
PharmGKB Accession Id: PA24413

Details

Cytogenetic Location: chr9 : q34.12 - q34.12
GP mRNA Boundary: chr9 : 133588266 - 133763062
GP Gene Boundary: chr9 : 133578266 - 133766062
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

The ABL1 gene is an important cancer PGx diagnostic pharmacogene as part of the BCR-ABL fusion protein (see drug label annotations for bosutinib, busulfan, dasatinib, homoharringtonine, imatinib, nilotinib, ponatinib).

The ABL1 proto-oncogene encodes a tyrosine kinase [Article:2676087]. In the 1980's it was shown to be involved in the Philadelphia chromosome (Ph+), a translocation event that is characteristic of chronic myelocytic leukaemia, CML [Article:6960256]. The fusion of ABL1 and BCR results in an overactive tyrosine kinase [Article:2676087]. There is heterogeneity in the size of the BCR-ABL fusion proteins generated due to different breakpoints of the translocation. The breakpoints in the ABL gene on chromosome 9 occur usually at exon a2, the breakpoints in BCR on chromosome 22 are between exons e12-e16 (also known as b1-b5) [Article:25949834]. Some of the breakages too small to be seen by karyotype, ie classified as Ph-, but still harbor the BCR-ABL fusion protein [Article:25949834].

One of the first targeted anti-cancer therapies, imatinib, was developed by testing compounds that inhibited growth of BCR-ABL positive cell lines [Article:9345054]. Imatinib was approved in 2001 by the FDA for the treatment of CML 12941424. Imatinib binds to the ATP-binding site of the ABL kinase and stabilizes the protein in this inactive conformation [Article:15256671]. More than 100 different mutations in BCR-ABL have been reported that confer resistance to imatinib [Articles:25132497, 15256671]. The key residues in BCR-ABL are: M244, G250, Q252, Y253, E255, V299, F311, T315, F317, M351, F359, and H396 [Article:25132497]. Second generation ABL inhibitors such as desatinib were able to inhibit mutant ABL tyrosine kinases except for T315I [Article:15256671]. Ponatinib was recently approved to treat imatinib-resistant Ph+ leukemias including those with T315I [Article:25132497].

Citation
M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "Pharmacogenomics Knowledge for Personalized Medicine" Clinical Pharmacology & Therapeutics (2012) 92(4): 414-417. Full text
History

Submitted by Caroline F Thorn

Key Publications
  1. Optimal Molecular Methods in Detecting p190 (BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature. Case reports in hematology. 2015. Sonu Rebecca J, Jonas Brian A, Dwyre Denis M, Gregg Jeffrey P, Rashidi Hooman H. PubMed
  2. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer cell. 2014. Zabriskie Matthew S, Eide Christopher A, Tantravahi Srinivas K, Vellore Nadeem A, Estrada Johanna, Nicolini Franck E, Khoury Hanna J, Larson Richard A, Konopleva Marina, Cortes Jorge E, Kantarjian Hagop, Jabbour Elias J, Kornblau Steven M, Lipton Jeffrey H, Rea Delphine, Stenke Leif, Barbany Gisela, Lange Thoralf, Hernández-Boluda Juan-Carlos, Ossenkoppele Gert J, Press Richard D, Chuah Charles, Goldberg Stuart L, Wetzler Meir, Mahon Francois-Xavier, Etienne Gabriel, Baccarani Michele, Soverini Simona, Rosti Gianantonio, Rousselot Philippe, Friedman Ran, Deininger Marie, Reynolds Kimberly R, Heaton William L, Eiring Anna M, Pomicter Anthony D, Khorashad Jamshid S, Kelley Todd W, Baron Riccardo, Druker Brian J, Deininger Michael W, O'Hare Thomas. PubMed
  3. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.). 2004. Shah Neil P, Tran Chris, Lee Francis Y, Chen Ping, Norris Derek, Sawyers Charles L. PubMed
  4. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997. Deininger M W, Goldman J M, Lydon N, Melo J V. PubMed
  5. The molecular biology of CML: a review. Cancer investigation. 1989. Leibowitz D, Young K S. PubMed
  6. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982. de Klein A, van Kessel A G, Grosveld G, Bartram C R, Hagemeijer A, Bootsma D, Spurr N K, Heisterkamp N, Groffen J, Stephenson J R. PubMed
Variant Summaries rs121913459
Drugs
Diseases
Pathways
No related genes are available

Curated Information ?

Curated Information ?

Publications related to ABL1: 33

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expanding the computational toolbox for interrogating cancer kinomes. Pharmacogenomics. 2016. Tan Aik Choon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic agreement between two cancer cell line data sets. Nature. 2015. Cancer Cell Line Encyclopedia Consortium, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature. 2015. Pemovska Tea, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Optimal Molecular Methods in Detecting p190 (BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature. Case reports in hematology. 2015. Sonu Rebecca J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report. Pharmacogenomics. 2015. Venton Geoffroy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer cell. 2014. Zabriskie Matthew S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. American journal of hematology. 2013. Cortes J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leukemia & lymphoma. 2012. Steegmann Juan Luis, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert review of anticancer therapy. 2012. Keller-V Amsberg Gunhild, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. Molecular cancer therapeutics. 2012. Sen Rupashree, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacokinetics of Dasatinib for Philadelphia- Positive Acute Lymphocytic Leukemia with Acquired T315I mutation. Journal of hematology & oncology. 2012. Takahashi Naoto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL. Cancer cell. 2011. Mali Raghuveer Singh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011. Boulos Nidal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clinical pharmacology and therapeutics. 2010. Stegmeier F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor suppressor FUS1 signaling pathway. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008. Ji Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The cancer biomarker problem. Nature. 2008. Sawyers Charles L. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta crystallographica. Section D, Biological crystallography. 2007. Cowan-Jacob Sandra W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Imatinib and regression of type 2 diabetes. The New England journal of medicine. 2005. Veneri Dino, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.). 2004. Shah Neil P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report. Biological procedures online. 2004. Iqbal Zafar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003. Ross Mary E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003. Corbin Amie S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Imatinib mesylate--a new oral targeted therapy. The New England journal of medicine. 2002. Savage David G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Roots of clinical resistance to STI-571 cancer therapy. Science (New York, N.Y.). 2001. Barthe C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, N.Y.). 2001. Gorre M E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000. Mahon F X, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000. le Coutre P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997. Deininger M W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The molecular biology of CML: a review. Cancer investigation. 1989. Leibowitz D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982. de Klein A, et al. PubMed

LinkOuts

NCBI Gene:
25
OMIM:
189980
UCSC Genome Browser:
NM_005157
RefSeq RNA:
NM_005157
NM_007313
RefSeq Protein:
NP_005148
NP_009297
RefSeq DNA:
NG_012034
NT_035014
UniProtKB:
ABL1_HUMAN (P00519)
Q59FK4_HUMAN (Q59FK4)
Ensembl:
ENSG00000097007
GenAtlas:
ABL1
GeneCard:
ABL1
MutDB:
ABL1
ALFRED:
LO037753Z
HuGE:
ABL1
Comparative Toxicogenomics Database:
25
ModBase:
P00519
HumanCyc Gene:
HS01874
HGNC:
76

Common Searches